288 related articles for article (PubMed ID: 32302778)
1. Mass Spectrometry-Based Method Targeting Ig Variable Regions for Assessment of Minimal Residual Disease in Multiple Myeloma.
Martins CO; Huet S; Yi SS; Ritorto MS; Landgren O; Dogan A; Chapman JR
J Mol Diagn; 2020 Jul; 22(7):901-911. PubMed ID: 32302778
[TBL] [Abstract][Full Text] [Related]
2. Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.
Zajec M; Jacobs JFM; Groenen PJTA; de Kat Angelino CM; Stingl C; Luider TM; De Rijke YB; VanDuijn MM
J Proteome Res; 2018 Mar; 17(3):1326-1333. PubMed ID: 29424538
[TBL] [Abstract][Full Text] [Related]
3. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
4. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.
Szczepek AJ; Seeberger K; Wizniak J; Mant MJ; Belch AR; Pilarski LM
Blood; 1998 Oct; 92(8):2844-55. PubMed ID: 9763569
[TBL] [Abstract][Full Text] [Related]
5. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
Foureau D; Bhutani M; Guo F; Rigby K; Leonidas M; Tjaden E; Fox A; Atrash S; Paul B; Voorhees PM; Usmani SZ
Cancer Med; 2021 Oct; 10(20):6933-6936. PubMed ID: 34494717
[TBL] [Abstract][Full Text] [Related]
6. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia.
Ozaki S; Abe M; Wolfenbarger D; Weiss DT; Solomon A
Clin Immunol Immunopathol; 1994 May; 71(2):183-9. PubMed ID: 8181187
[TBL] [Abstract][Full Text] [Related]
7. Quantification of peptides from immunoglobulin constant and variable regions by LC-MRM MS for assessment of multiple myeloma patients.
Remily-Wood ER; Benson K; Baz RC; Chen YA; Hussein M; Hartley-Brown MA; Sprung RW; Perez B; Liu RZ; Yoder SJ; Teer JK; Eschrich SA; Koomen JM
Proteomics Clin Appl; 2014 Oct; 8(9-10):783-95. PubMed ID: 24723328
[TBL] [Abstract][Full Text] [Related]
8. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS/MS.
Barnidge DR; Tschumper RC; Theis JD; Snyder MR; Jelinek DF; Katzmann JA; Dispenzieri A; Murray DL
J Proteome Res; 2014 Apr; 13(4):1905-10. PubMed ID: 24552626
[TBL] [Abstract][Full Text] [Related]
9. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
10. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
11. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
12. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
[TBL] [Abstract][Full Text] [Related]
13. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
14. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
15. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma.
Gharagozloo S; Sharifian RA; Mageed RA; Shokri F
Pathol Oncol Res; 2000; 6(3):185-90. PubMed ID: 11033458
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
18. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
[TBL] [Abstract][Full Text] [Related]
19. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
20. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
van Velzen JF; van den Blink D; Bloem AC
Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
